Overview

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Status:
COMPLETED
Trial end date:
2024-10-29
Target enrollment:
Participant gender:
Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
Phase:
PHASE4
Details
Lead Sponsor:
Sun Pharmaceutical Industries Limited
Treatments:
Adapalene
Clascoterone
Gels